ORION CORPORATION STOCK EXCHANGE RELEASE 19 JANUARY 2016 at 9:30 A.M. EET
Publishing of Orion Corporation's Financial Statement Release for 2015 on 2 February 2016
Orion will publish Financial Statement Release for 2015 on Tuesday, 2 February 2016 approximately at 12:00 noon Finnish time (EET). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/en/investors promptly after the publishing.
News conference for analysts and media
A news conference for analysts and media will be held on Tuesday 2 February 2016 at 13:30 EET at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review. Questions can be asked after the result presentation also via teleconference.
Participants should be prepared to present a photo ID on request.
Live webcast and conference call
A link to the live webcast will be available at Orion's website www.orion.fi/en/investors.
The conference call ID is 7489965 and the phone numbers to participate the conference are:
Finland: +358 (0)9 6937 9590
Sweden: +46 (0)8 5065 3936
UK: +44 (0)20 3427 1919
USA: +1 646 254 3362
News conference recordings
A recording of the event in English and a recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.
The silent period preceding the publication is ongoing and continues until the disclosure.
| Timo Lappalainen|
President and CEO
| Jari Karlson|
Tuukka Hirvonen, Communications Manager, IR & Financial Communications
tel. +358 10 426 2721
Orion is a globally operating Finnish company developing pharmaceuticals and diagnostic tests - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2014 amounted to EUR 1,015 million and the company had about 3,500 employees. Orion's A and B shares are listed on NASDAQ Helsinki.